CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastati... (h Stage III or Stage IVmalignant melanom...)

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma

Date:10/24/2007

h Stage III or Stage IV malignant melanoma.

"We are encouraged by these initial clinical results on CR011-vcMMAE and the suggestion of potential anti-cancer activity in patients with previously progressive disease, which support continued evaluation of this antibody-drug conjugate in the treatment of advanced melanoma. We continue to enroll patients into the trial, and look forward to further characterizing the activity of this novel therapeutic," commented Dr. Mario Sznol, co-Principal Investigator, Co-Director of the Melanoma Program at the Yale Cancer Center in New Haven, CT.

This open-label, dose-escalation study conducted at the Yale Cancer Center, New Haven, CT, MD Anderson Cancer Center, Houston, TX, and The Angeles Clinic and Research Institute, Santa Monica, CA, is evaluating the safety, tolerability and pharmacokinetics of CR011-vcMMAE for patients with unresectable Stage III or Stage IV melanoma who have failed no more than one prior line of cytotoxic therapy. The first part of the trial will evaluate cohorts of patients receiving increasing doses of CR011-vcMMAE to determine the MTD. After determination of the MTD, up to approximately 32 additional patients will be enrolled and treated at the MTD to further define the safety and efficacy of CR011-vcMMAE.

CuraGen will host a conference call on Thursday, October 25, 2007 at 5:00 p.m. Eastern time to discuss these Phase I results on CR011-vcMMAE and the four posters discussing Phase I and Phase II clinical trial results with belinostat being presented at the AACR-NCI-EORTC International Conference.

Conference Call Details and Dial-in Information

Date: Thursday, October 25, 2007

Time: 5:00 p.m. Eastern time

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 21928842

Webcast: Access to the live webcast and presentation are available at

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastati...(h Stage III or Stage IVmalignant melanom...),Health